Amphastar Pharmaceuticals (AMPH) Total Debt (2013 - 2026)

Amphastar Pharmaceuticals' Total Debt history runs 14 years deep, the most recent figure standing at $611.5 million for Q1 2026.

• In Q1 2026, Total Debt rose 1.22% year-over-year to $611.5 million; the TTM figure through Mar 2026 stood at $611.5 million (up 1.22% YoY), while the FY2025 annual figure was $610.4 million, up 1.42% from the prior year.
• Total Debt was $611.5 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $610.4 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $638.6 million in Q3 2023 to a low of $75.0 million in Q1 2023.
• Historically, Total Debt has averaged $443.1 million across 5 years, with a median of $594.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Debt soared 743.74% in 2023, then retreated 6.57% in 2024.
• A 5-year view of Total Debt shows it stood at $75.9 million in 2022, then jumped by 677.51% to $590.0 million in 2023, then rose by 2.01% to $601.9 million in 2024, then advanced by 1.42% to $610.4 million in 2025, then advanced by 0.18% to $611.5 million in 2026.
• The last three Total Debt figures came in at $611.5 million (Q1 2026), $610.4 million (Q4 2025), and $609.5 million (Q3 2025), per Business Quant data.